Skip to main content
Keymed Biosciences Inc. logo

Keymed Biosciences Inc. — Investor Relations & Filings

Ticker · 2162 ISIN · KYG5252B1023 LEI · 549300600S6M6SOT7P36 HKEX Manufacturing
Open in API
Filings indexed 775 across all filing types
Latest filing 2026-05-06 Regulatory Filings
Country KY Cayman Islands
Listing HKEX 2162

About Keymed Biosciences Inc.

http://www.keymedbio.com

Keymed Biosciences Inc. is a biopharmaceutical company specializing in the in-house discovery and development of innovative biological therapies. The company focuses on therapeutic areas with urgent unmet clinical needs, primarily autoimmune diseases, other chronic conditions, and oncology. Keymed operates an integrated, full-chain platform covering source innovation, clinical development, production, and commercialization. It maintains a diversified and globally competitive product pipeline, leveraging its advanced R&D engine and cGMP-compliant manufacturing capabilities to deliver high-quality, affordable treatments.

Recent filings

Filing Released Lang Actions
Monthly Return of Equity Issuer on Movements in Securities for the month ended 30 April 2026
Regulatory Filings Classification · 95% confidence The document is a monthly return filed with the Hong Kong Exchanges and Clearing Limited (HKEX) regarding movements in securities for Keymed Biosciences Inc. It details authorized share capital, issued shares, public float sufficiency, and confirms no changes in share options, warrants, convertibles, or other agreements. The document is a regulatory submission reporting share capital and shareholding movements for the month ended 30 April 2026. It is not a financial report, earnings release, or management discussion. It is a regulatory filing related to share capital and public float compliance under HKEX rules. The document is not a report publication announcement or certification but a formal regulatory disclosure. Therefore, the most appropriate classification is Regulatory Filings (RNS).
2026-05-06 English
FORM OF PROXY FOR USE AT ANNUAL GENERAL MEETING
Proxy Solicitation & Information Statement Classification · 98% confidence The document is a "Form of Proxy" for use at the Annual General Meeting, which is a materials sent to shareholders to solicit their votes and provide information in advance of the meeting. This falls squarely under "Proxy Solicitation & Information Statement" (PSI).
2026-04-29 English
(1) GENERAL MANDATES TO ISSUE SHARES AND REPURCHASE SHARES; (2) RE-ELECTION OF DIRECTORS; (3) RE-APPOINTMENT OF AUDITOR; AND (4) NOTICE OF ANNUAL GENERAL MEETING
AGM Information Classification · 95% confidence The document is a circular from the board of Keymed Biosciences Inc. regarding the upcoming Annual General Meeting (AGM). It includes details about general mandates to issue and repurchase shares, re-election of directors, re-appointment of auditor, and the notice of the AGM itself. The content includes proxy forms, explanatory statements, and resolutions to be voted on at the AGM. This type of document is typically classified as AGM Information (AGM-R) because it contains materials and notices related to the AGM rather than the full annual report or financial statements. The document length is substantial (15,000 characters), indicating it is not a brief announcement but a full circular for the AGM. Therefore, the appropriate classification is AGM Information (AGM-R).
2026-04-29 English
NOTICE OF ANNUAL GENERAL MEETING
Proxy Solicitation & Information Statement Classification · 90% confidence The document is a formal notice of the Annual General Meeting, issued to shareholders with the agenda, resolutions to be voted on, proxy instructions, and related meeting details. It is not the actual meeting minutes or presentations (AGM-R), nor a results announcement (DVA). It is precisely the type of material distributed to shareholders to provide information and request votes ahead of the meeting, matching the definition of a Proxy Solicitation & Information Statement (PSI).
2026-04-29 English
2025 ANNUAL REPORT
Annual Report Classification · 100% confidence The document is titled '2025 ANNUAL REPORT' for Keymed Biosciences Inc. It contains typical sections of an annual report such as Chairman's Statement, Financial Highlights, Management Discussion and Analysis, Directors and Senior Management, Corporate Governance Report, Environmental, Social and Governance Report, Report of Directors, Independent Auditor's Report, and detailed financial statements including Consolidated Statement of Profit or Loss, Comprehensive Income, Financial Position, Changes in Equity, Cash Flows, Notes to Financial Statements, and a Five Year Financial Summary. The document length is 15,000 characters, indicating a full report rather than a brief announcement. The content and structure clearly match the definition of an Annual Report (10-K) which covers company activity and full financial performance for the fiscal year ended December 31, 2025.
2026-04-29 English
SUPPLEMENTAL ANNOUNCEMENT TO DISCLOSEABLE TRANSACTION DISPOSAL OF EQUITY INTEREST IN OURO MEDICINES
M&A Activity Classification · 85% confidence The document is a supplement to a previously disclosed transaction involving the disposal of the company’s minority equity interest in another entity. It details conditions precedent, pricing, expected proceeds, and intended use of funds – all hallmarks of an M&A transaction announcement rather than an annual or interim report, earnings release, management discussion, or regulatory notice. Therefore, it fits the M&A Activity category.
2026-04-15 English

Browse filings by year

25 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.